Licensing & partnership
Stipple Bio Partners With Lilly
Stipple Bio and Lilly entered a multi-target, multi-modality oncology research and licensing collaboration. Stipple will use its Pointillist Platform to discover tumor-specific binders, while Lilly will apply its oncology technologies and holds exclusive worldwide development and commercialization rights. Stipple will receive an undisclosed upfront payment and equity investment, and is eligible for up to $5.9 billion in milestones plus tiered royalties.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.